Drug intelligence / Profile preview

lactobacillus reuteri + omeprazole

Development stage: Unknown
Lead developer: BioGaia
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Lactobacillus reuteri + omeprazole** is a combination therapy comprised of a probiotic bacterium, *Lactobacillus reuteri*, and the proton pump inhibitor (PPI) omeprazole. This combination has been investigated for the treatment of *Helicobacter pylori* infection and peptic ulcer disease, particularly as an alternative to standard triple therapy which involves antibiotics. *L. reuteri* acts mainly by producing antimicrobial compounds (primarily reuterin) that inhibit the growth of *H. pylori* and other pathogens, while omeprazole suppresses gastric acid production, creating an environment hostile to *H. pylori* survival and facilitating probiotic colonization. Clinical trials suggest that this combination can reduce *H. pylori* load, improve gastrointestinal symptoms, and may increase eradication rates in some contexts, all while offering a favorable safety and tolerability profile[1][2][5].

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)Helicobacter pylori adhesion to gastric mucosal glycolipid receptors

Beyond the preview

Go deeper on lactobacillus reuteri + omeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus reuteri + omeprazole.

Explore the full profile